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Molecular pathogenesis of ADPKD: The polycystin complex
gets complex. Autosomal-dominant polycystic kidney disease
(ADPKD) is one of the most common human monogenic dis-
eases with an incidence of 1:400 to 1:1000. It is characterized
by the progressive development and enlargement of focal cysts
in both kidneys, typically resulting in end-stage renal disease
(ESRD) by the fifth decade. The cystogenic process is highly
complex with a cellular phenotype consistent with “dediffer-
entiation” (i.e., a high proliferative rate, increased apoptosis,
altered protein sorting, changed secretory characteristics, and
disorganization of the extracellular matrix). Although cystic
renal disease is the major cause of morbidity, the occurrence
of nonrenal cysts, most notably in the liver (occasionally re-
sulting in clinically significant polycystic liver disease) and the
increased prevalence of other abnormalities including intracra-
nial aneurysms, indicate that ADPKD is a systemic disorder.
Following the identification of the first ADPKD gene, PKD1,
10 years ago and PKD2 2 years later, considerable progress
has been made in defining the etiology and understanding the
pathogenesis of this disorder, knowledge that is now leading to
the development of several promising new therapies. The pur-
pose of this review is to summarize our current state of knowl-
edge as to the structure and function of the PKD1 and PKD2
proteins, polycystin-1 and -2, respectively, and explore how mu-
tation at these loci results in the spectrum of changes seen in
ADPKD.
AUTOSOMAL-DOMINANT POLYCYSTIC
KIDNEY DISEASE (ADPKD) IS GENETICALLY
HETEROGENEOUS
Mutation to PKD1 (chromosome region 16p13.3) is
the most common cause of ADPKD (∼ 86% cases) with
most of the remainder due to changes to PKD2 (4q22).
However, the description of possible unlinked families
indicates that at least one other unknown gene may be as-
sociated with ADPKD. The clinical phenotypes of PKD1
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and PKD2 are closely related; they were only recognized
as diseases with different etiologies by genetic linkage
analysis in the late 1980s. This phenotypic similarity in-
cludes both the nature of the renal disease and the range
of extrarenal manifestations (cases of polycystic liver dis-
ease and intracranial aneurysms are associated with both
genes). However, there are differences: PKD2 is a sig-
nificantly milder disease in terms of the mean age at di-
agnosis, a lower prevalence of hypertension, and a later
age at onset of end-stage renal disease (ESRD) (PKD1,
54.3 years and PKD2, 74.0 years) [1]. Furthermore, while
on average disease severity is similar between males and
females in PKD1, PKD2 females have a significantly bet-
ter prognosis (age at onset of ESRD in males, 68.1 years
and in females, 76.0 years). The reason for this difference
is unclear [2, 3]. Within both disorders, there is a wide
range of intrafamilial phenotypic variability, seen both in
terms of the severity of renal disease and manifestations
of extrarenal abnormalities, indicating that genetic modi-
fying loci and environment factors significantly influence
the course of the disease [2].
THE MUTATION SPECTRUM
PKD1 is a complex gene with 46 exons that generates a
large transcript (∼14 kb) containing a long open-reading
frame predicted to encode a 4302aa protein. Character-
ization of the gene structure and identification of mu-
tations has been complicated by genomic duplication of
the 5′ region of PKD1 (to exon 33) such that approxi-
mately six copies of PKD1-like genes, with various re-
arrangements relative to PKD1, are located in 16p13.1.
Sequence similarity of these pseudogenes (many of which
encode transcripts but probably not significant protein
products) to PKD1 means that particular anchored, long
and locus-specific amplification methods are required to
characterize and screen PKD1 for mutations [4]. PKD2
has 15 exons, generates a ∼5 kb transcript, and encodes
a protein of 968aa.
Both PKD1 and PKD2 exhibit marked allelic hetero-
geneity, with approximately 200 different PKD1 and over
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50 different PKD2 mutations described [3–5]. The major-
ity of these are unique to a single family, illustrating the
complexity of gene-based diagnostics for these disorders
and indicating that a significant level of new mutation
is occurring [4]. Most mutations are predicted to trun-
cate the protein (due to frame-shifting deletion/insertion,
nonsense changes, or splicing defects), but a significant
level of in-frame and missense changes have also been
described [3, 4]. Mutations are found throughout both
genes, although more PKD1 changes are found in the
3′ half of the gene [4]. This pattern of mutation is con-
sistent with inactivation of one allele but recent geno-
type/phenotype correlations in PKD1 suggest that not
all mutations may have the same phenotypic outcome.
In PKD1, mutations 5′ to the median are associated with
more severe disease (average age at onset of ESRD at 5′,
53 years and at 3′, 56 years) and a significantly greater risk
of developing intracranial aneurysms [2, 5]. This associ-
ation is not related to mutation type and may be due to
the proposed cleavage of polycystin-1 into two different
proteins (see later), with mutations to each half having
potentially different phenotypic consequences [5, 6]. As
yet, no clear phenotype/genotype correlations have been
reported for PKD2 [3].
MUTATIONAL MECHANISM
A two-hit mechanism of cyst formation has been pro-
posed for ADPKD (consisting of a germ line mutation to
one allele and a somatic mutation to the other). This is an
attractive hypothesis which could help explain both the
focal nature of cyst development and the striking pheno-
typic variability seen in most families. Evidence of epithe-
lial cell clonality within individual cysts and the detection
of somatic mutations in cells isolated from a proportion
of renal and hepatic cysts supports the two-hit hypothesis
[7–9]. Furthermore, embryonic renal cyst development in
homozygous knockout Pkd1 or Pkd2 animals, and partic-
ularly the progressive cystic disease seen associated with
the Pkd2WS25 mutant (that has a Pkd2 allele prone to
inactivation by somatic mutation), are consistent with a
two-hit model of cyst development [10, 11]. However,
there remain questions as to whether the two-hit mech-
anism is the only means to generate a cyst and indeed,
whether these somatic events may be later events more
important for cyst expansion and progression rather than
initiation [12].
Persistent or even enhanced immunoreactivity for
polycystin-1 or -2 is often detected in cystic epithelia but
it is not clear if this signal represents functional protein
[13–16]. Recent studies indicate that multiple karyotypic
changes resulting in chromosomal imbalances are asso-
ciated with cyst development, not just loss of heterozy-
gosity (LOH) at the normal ADPKD allele (although
LOH at 16p was found at a higher frequency) [17]. Pro-
gressive dedifferentiation of cystic epithelia during cyst
enlargement in the Pkd2WS25/− model also indicates that
cyst development and expansion may be dynamic and
the result of more than a simple two-hit process [18]. A
situation that illustrates the complexity of cyst develop-
ment is the finding of somatic PKD2 mutations in PKD1
cystic epithelia and vice versa, suggesting that cells that
are transheterozygous may be prone to cyst development
[19, 20]. However, it is apparent that this pattern of mu-
tation cannot fully explain cyst initiation as patients and
mice that are trans-heterozygous for a germ line PKD1
and PKD2 mutation have been described [21, 22]. Al-
though these patients/animals have more severe disease
than cases with either mutation alone, the difference is
not dramatic (i.e., not every renal tubular cell gives rise
to a cyst). These somatic events to the other ADPKD
gene therefore appear to be akin to modifying genetic
changes that increase the risk of cyst development (or has-
ten their progression) rather than cyst initiating events.
Another example where a mutation to a second gene
(in the germ line) can hasten cyst development and ex-
pansion are cases in which both PKD1 and a tuberous
sclerosis gene (TSC2) allele are mutated due to a large
contiguous gene deletion [23]. These patients have TSC
and severe early-onset PKD, indicating a likely synergis-
tic role for polycystin-1 and tuberin (the TSC2 protein)
in cyst development [24]. A possible mechanism which
could account for this phenotype is the finding that tu-
berin plays a role in trafficking polycystin-1 to the lateral
cell membrane [25].
When considering the mutational mechanism, it is
worth noting that loss of a single allele (haploinsuffi-
ciency) may be sufficient in itself to elicit a phenotypic
change. Recent studies have shown that Pkd2+/− vascular
smooth muscle cells express a lower level of polycystin-2
and have altered intracellular Ca2+ homeostasis [26]. In
addition, haploinsufficient Pkd2 mice have reduced sur-
vival (not due to renal failure) indicating that a dosage
reduction of polycystin-2 itself exerts a phenotypic load
[27]. This is, however, not the case with Pkd1 heterozy-
gotes who have a normal life span. Overexpression of
functional polycystin-1 via a genomic transgene leads to
age-related cysts in the kidney and liver, suggesting that
an imbalance in the relative amounts of one polycystin
protein can also result in cyst development. One possible
explanation is that some polycystin complexes become
inactivated due to the stoichiometric imbalance between
the two proteins [28]. Given the available data, it seems
reasonable to conclude that cystogenesis is a complex
process. Cyst development requires a germ line muta-
tion but beyond this, the likelihood of cyst formation is
influenced by a number of different factors. These in-
clude somatic genetic events at the other (normal) al-
lele, mutations at the other ADPKD gene and possibly a
wide array of other genetic loci. In effect, these loci act as
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Fig. 1. Predicted structure and topology of polycystin-1 and polycystin-2.The predicted topology and structure of polycystin-1 and polycystin-2
indicates that they are glycosylated integral membrane proteins. Polycystin-1 has multiple structural motifs with predicted protein [leucine-rich and
polycystic kidney disease (PKD) repeats], carbohydrate (C-type lectin), and lipid binding (PLAT) capacity. Polycystin-1 has a highly conserved
G protein–coupled receptor proteolytic cleavage site (GPS) indicating that it may function as N-terminal and C-terminal products linked by
noncovalent bonds. Polycystin-2 has extensive similarity to voltage-gated calcium (VACC) or transient receptor potential (TRP) channels.
modifiers of disease presentation in ADPKD. Beyond the
genetic events, stochastic factors probably also influence
whether a cell, haploinsufficient for an ADPKD muta-
tion, is diverted into a cystogenic pathway. Another factor
which could modify the cystic phenotype is the presence
of partially functional (mutant) polycystin-1 protein (e.g.,
in Pkd1 del34 mice) [29] or alternatively, nonfunctional
mutant protein which could act in a dominant-negative
manner (note added in proof).
THE POLYCYSTIN PROTEIN FAMILY
Sequencing of the PKD1 and PKD2 transcripts al-
lowed the structure of the disease proteins to be mod-
eled (Fig. 1). These structures have been refined by the
characterization of orthologs (mouse, rat, and Fugu fish)
and an array of homologous proteins characterized in
humans (Table 1), other mammals, and more primitive
species [30–32]. In addition, laboratory-based structural
and functional analysis has helped to refine and confirm
the likely structures. Only polycystin-1 and -2 are known
to be associated with PKD but the other homologues
have provided an insight into the likely ion channel role
of polycystin-2–like proteins and the possible proteolytic
cleavage of polycystin-1–like proteins. Recent studies of
related Caenorhabditis elegans and Drosophila proteins
have suggested a likely functional role for the polycystins
in primary cilia or flagella. Of interest, the sea urchin
polycystin-1 (suREJ3) and polycystin-2 (suPC2) ortho-
logues have been shown to colocalize at the sperm acroso-
mal vesicle and coimmunoprecipitate—this could impli-
cate a suREJ3/suPC2 complex in the acrosomal reaction
[33].
Polycystin-1 is a large (460 kD), integral membrane
glycoprotein (11 transmembrane passes) with an exten-
sive extracellular region containing a number of different
domains, many of which are involved in protein-protein
or protein-carbohydrate interactions in other proteins
and a short C-terminal tail. A possible role in cell/cell
and/or cell/matrix interactions has been proposed for this
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Table 1. Polycystin-1 and polycystin-2 human homologues
Protein Gene Chromosome Function Human disease Reference
Polycystin-1 PKD1 16p13.3 ? Adhesion; ? channel
regulator; ?
mechanosensor
ADPKD [95]
Polycystin-REJ PKDREJ 22q13 ? Acrosome reaction Unknown [96]
Polycystin-1L1 PKD1L1 7p12–13 ? Unknown [97]
Polycystin-1L2 PKD1L2 16q–22–23 ? Unknown [98]
Polycystin-1L3 PKD1L3 16q–22–23 ? Unknown [98]
Polycystin-2 PKD2 4q21–23 Ion channel; LR
determination; ?
acrosome reaction
ADPKD [33, 58, 99]
Polycystin-L
(polycystin-2L;
polycystin-2L1)
PKDL(PKD2L;
PKD2L1)
10q24–25 Ion channel Unknown [100, 101]
Polycystin-2L2 PKD2L2 5q31 ? Unknown [102]
ADPKD is autosomal-dominant polycystic kidney disease.
protein but, so far, no ligand has been identified with cer-
tainty (refer to Table 4). Polycystin-2 has homology with
the final six transmembrane domain region of polycystin-
1 and topologic and sequence homology with voltage-
activated (VAC) and transient receptor potential (TRP)
channels [34]. The similarity to the TRP proteins has
led to its inclusion (along with other polycystin-2–like
proteins) as a new subfamily (TRPP) within the TRP
superfamily. Predictions from amino acid sequence (60
N-linked sites are predicted on polycystin-1) and experi-
mental evidence indicates that the polycystins are glyco-
sylated with several different glycol forms of polycystin-1
identified [35]. Preliminary evidence indicates that the
C-terminus of polycystin-1 can also be phosphorylated
by protein kinase A and a src-like tyrosine kinase. Acti-
vation of signaling may occur through this modification
[36]. Polycystin-2 is constitutively phosphorylated by ca-
sein kinase-2 and this may modulate its channel activity
[37].
Another posttranslational modification to polycystin-
1 that has been proposed is cleavage to generate
more than one product. Sequence homology with the
latrophilin/CL-1 receptors identified a G-protein coupled
receptor proteolytic site (GPS) where the latrophilin/CL-
1 proteins are cleaved in the PKD1-like polycystins. Re-
cent data from ectopically expressed polycystin-1 have
demonstrated partial cleavage at this site; cleavage did
not occur in an array of mutant polycystin-1 proteins
with missense mutations in the adjacent receptor for egg
jelly (REJ) region [6]. Cleavage at a similar location con-
curs in the related sea urchin protein suREJ3. By analogy
with the latrophilin/CL-1 receptors, the cleaved N- and C-
terminal products remain tethered, although in this case
the linkage is noncovalent. The functional significance of
this cleavage event and whether the two products always
remain tethered as part of the same complex are ques-
tions that are not yet fully resolved.
Polycystin-1 and -2 are thought to interact via their C-
terminal tails to form a complex. The first evidence for
this interaction came from yeast two hybrid studies with
the interacting region on polycystin-1 within a conserved
coiled-coil domain [38, 39]. In addition, polycystin-2 has a
region upstream of the heterodimerization domain which
appeared to mediate homodimerization. One study also
suggested that polycystin-1 could homodimerize via its C-
terminus but this was not confirmed in a second study [38,
39]. There is now good biochemical evidence supporting
an interaction between the polycystins in vivo (see later).
CELLULAR AND SUBCELLULAR
LOCALIZATION OF POLYCYSTIN-1 AND
POLYCYSTIN-2
Consistent with the formation of a polycystin com-
plex, there is considerable overlap in the expression
pattern of the two proteins. Both proteins are widely
expressed in epithelial cells, vascular smooth muscle, car-
diac myocytes, and in other locations (see [40] for details).
However, there are differences, most notably during de-
velopment. While polycystin-1 is expressed at the high-
est level in the embryo and significantly down-regulated
shortly after birth, polycystin-2 expression is maintained
at a constant level into adult life.
The subcellular localization of both proteins has been
most extensively studied in renal epithelial cells with mul-
tiple different locations of the proteins identified [40].
There is evidence of polycystin-1 expression at a variety
of lateral membrane junctions (tight junctions, adherens
junctions, desmosomes), focal adhesions, apical vesicles,
and primary cilia [35, 41–47]. In contrast, polycystin-2 has
been localized predominantly to the endoplasmic retic-
ulum but also to basolateral plasma membranes, lamel-
lopodia, primary cilia, and mitotic spindles [35, 47–52].
The distribution of these proteins (Table 2) indicates
a complex picture that may also be developmentally
regulated and suggest that the proteins may sometimes
act independently. However, it is worth noting that
polycystin-1 expression in the plasma membrane and
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Table 2. Subcellular localization of polycystin-1 and polycystin-2 in mammalian cells
Subcellular compartment Cells or tissues Putative function Reference
Polycystin-1
Primary cilium Mouse collecting duct cells ? Regulator of flow-sensitive channel [47, 76]
Tight junctions Adult rat kidney Junctional permeability; cell polarity [41]
Desmosomes Madin-Darby canine kidney Cell-cell adhesion or signaling [43, 72, 103]
Adherens junctions Human fetal kidney; ADPKD cystic cells Cell-cell adhesion or signaling [42, 69]
Lateral cell membranes Human umbilical vein endothelial cells;
Madin-Darby canine kidney; mouse
collecting duct cells
Cell-cell adhesion or signaling [44, 68, 104]
Focal adhesions Human fetal collecting duct cells;
ADPKD cystic cells
Cell-matrix adhesion [45]
Apical vesicles Human fetal kidney; G401 tumor cells Recycling compartment [16, 46]
Endoplasmic reticulum Transfected COS-7 cells ? Regulation of PC2 channel [105]
Polycystin-2
Primary cilium Human proximal tubular cells; mouse
collecting duct cells
Flow-sensitive channel [47, 76, 83]
Endoplasmic reticulum LLCPK1; Madin-Darby canine kidney;
human embryonic kidney-293; adult
human kidney
Endoplasmic reticulum calcium channel [35, 48]
Basolateral membrane Adult human or rat kidney Cell-cell or cell-matrix adhesion [49, 106]
Lateral cell membrane Mouse collecting duct cells; inner
medullary collecting duct;
Madin-Darby canine kidney
Cell-cell adhesion or signaling [35, 50, 107]
Tight junctions Mouse collecting duct cells Junctional permeability; cell polarity [108]
Lamellopodia Transfected HeLa and COS7 cells Cell-matrix adhesion [51]
Mitotic spindles HeLa; LLCPK-1 ? Cell division [52]
LLCPK-1, porcine kidney cell line; HeLa, human cervical carcinoma cell line; COS7, African green monkey kidney cell line.
Table 3. Putative functions of polycystin-1 and the role of polycystin-2 interaction in mammalian systems
Function Model system PKD1 PKD2 Effect Reference
Cation channel Chinese hamster ovary cells FL + Cooperative [53]
Suppressing proliferation Madin-Darby canine kidney FL ?/+ Cooperative (JAK2
activation)
[66]
Inhibiting apoptosis Madin-Darby canine kidney FL ? [65]
Spontaneous tubulogenesis Madin-Darby canine kidney; inner
medullary collecting duct 3
FL or CT ? [65, 71]
Cell-cell adhesion Madin-Darby canine kidney;
PKD1 transgenic cells
E ? [67, 68]
Cell migration Inner medullary collecting duct 3 CT ? [71]
Cell-matrix adhesion Human fetal kidney epithelia;
ADPKD cystic cells
E ? [45]
Flow-sensitive ciliary channel Pkd1-del34 collecting duct cells E + Cooperative [76]
Abbreviations are: ADPKD, autosomal-dominant polycystic kidney disease; E, endogenous; FL, full-length; CT, C-terminus.
polycystin-2 in the endoplasmic reticulum does not pre-
clude interaction, as coupling between TRP channels
in the plasma membrane and inositol-1,4,5 triphosphate
(IP3) receptors in the adjacent endoplasmic reticulum has
been described.
Direct evidence of interaction between the poly-
cystins comes from heterologous expression of full-length
polycystin-1 and polycystin-2 in Chinese hamster ovary
(CHO) cells [53]. The specificity of these findings was
shown by the inability of naturally occurring polycystin-1
and -2 mutants, lacking the respective heterodimeriza-
tion domains to associate. Further studies confirmed the
physiologic nature of this interaction by showing that a
native complex could be isolated from human kidney and
other cultured cells [35, 54]. These studies further demon-
strated the existence of polycystin-2 multimers present in
native tissues and cells [35]. Treatment with PNGase F (to
cleave N-linked sugars) and endoglycosidase H (Endo
H) (to differentiate endoplasmic reticulum and plasma
membrane fractions) led to the identification of several
glycosylated forms of polycystin-1, including Endo H–
resistant and sensitive forms. One Endo H–sensitive and
a resistant form of polycystin-1 were found to interact
with polycystin-2, the latter of which was enriched in
plasma membrane fractions and coimmunoprecipitated
by polycystin-2 [35]. Membrane fractionation studies pro-
vided more evidence for the presence of a polycystin
complex in plasma membranes, although over 90% of
polycystin-2 was detected in the Golgi and endoplasmic
reticulum [35]. Table 3 summarizes the systems in which
interaction of the polycystins has been studied and the
likely functions of these complexes.
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Table 4. Proteins interacting with mammalian polycystin-1 and polycystin-2
Binding protein Primary method Putative function Reference
Polycystin-1
E-cadherin and catenins Co-IP Cell-cell adhesion [42]
Polycystin-1 (homophilic) Binding assays (NT) Cell-cell adhesion [67]
Intermediate filaments Y2H (CT) Cell-cell adhesion or signaling [103]
Vinculin, paxillin Co-IP Focal adhesions [45]
RGS7 Y2H (CT) Signaling [64]
Extracellular matix proteins Binding assays (NT) Cell-matrix adhesion [109, 110]
Siah-1 Y2H (CT) Protein stability [111]
Polycystin-2
TRPC1 Y2H (CT) Channel [34]
Polycystin-2 (homophilic) Y2H (CT) Channel [35, 39]
CD2AP Y2H (CT) Anchorage to actin [112]
Hax-1 Y2H (L5) Anchorage to actin [51]
Troponin-I Y2H (CT) Anchorage to actin [113]
Tropomyosin Y2H (CT) Anchorage to actin [114]
PIGEA-14 Y2H (CT) ? Endoplasmic reticulum-Golgi transport [115]
m-Dia1 Y2H (CT) ? Cell division or cell fate [52]
Abbreviations are: Co-IP, coimmunoprecipitation; Y2H, yeast 2 hybrid; CT, C-terminus; NT, N terminus; L5, loop 5.
Table 5. Extrarenal phenotypes of Pkd1 and Pkd2 mouse mutants
Exons Embryonic Vascular Cardiac Skeletal Heterozygous
Mutant disrupted lethality defect defect defect phenotype (cysts; age) Reference
Pkd1
Del 34 34 + (E18.5) − − + renal>9 m.liver>9 m.
pancreatic>22 m.
[10, 29, 59]
Pkd1L 4–45 + (E14.5-15.5) + (hem; edema) − − ? [41]
Del 17-21bgeo 1–21 + (E13.5-14.5) + (hem) + + renal>3 m.liver>19 m. [56]
Null 4 + (E13.5-16.5) + (edema) − + renal>2.5 m.liver>11m.
pancreatic>12 m.
[29]
−/− 2–6 + (E14.5) + (hem) + − ? [55]
Null 1 + (E12.5-birth) + (hem; edema) − − renal>3 m.no gross
liver cysts
[22]
Pkd2
WS25 (unstable) Disrupted exon 1
in IVS1
Live born − − − WS25+/−renal >2.5 m.
(many)liver >2.5 m.
[11, 27]
WS183 (null) 1 + (E13.5-18.5) + (hem; edema) + − +/−renal <3 m.
(rare)liver <9 m.
pancreatic none
[11, 27]
−/LacZ 1 + (E12.5-18.5) ? + − ? [57]
Abbreviations are: E, embryonic day; JAK2, Janus kinase 2; hem, hemorrhage.
WHAT ARE THE FUNCTIONS OF THE
POLYCYSTINS?
Insights into the likely functions of the polycystins
have come from functional analysis suggested by struc-
tural homology (Fig. 1), studies of the polycystin complex
in model systems (Table 3), identification of interacting
partners (see Table 4 for details), analysis of knockout
models (Table 5), and insights from other forms of PKD
(Table 6).
Knockout models of ADPKD
A number of different mouse models with targeted dis-
ruption to Pkd1 or Pkd2 have been described (see Table 5
for details). In all of the homozygous animals, renal devel-
opment appears to occur normally until embryonic day
(E) ∼ E14.5, after which renal cysts start to develop [10,
11, 41, 55, 56]. Since “normal” kidneys are formed up
to this time, it appears that the polycystins are not re-
quired for induction of the nephron but are necessary for
the normal maturation and maintenance of tubular ar-
chitecture. Liver cysts are not detected in homozygotes
but pancreatic cysts are seen from E13.5 [10, 11]. Ho-
mozygous Pkd1 and Pkd2 animals generally die during
the embryonic period. The early death of these embryos
is not related to the renal disease but may be due to car-
diac defects that have been described in some models
(see Table 5 for details). An additional common finding
is of edema and in some cases, vascular fragility leading
to localized and sometimes massive hemorrhage that may
also account for the early death of many embryos [41].
Pkd2−/− embryos have laterality defects manifesting as a
randomization of left/right asymmetry, suggesting a spe-
cific defect in the nodal ciliary signaling pathway which
establishes asymmetry of the body plan [57]. Recent data
indicate that polycystin-2 is expressed in nodal monocilia
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Table 6. Cystogenic proteins localized to primary cilia or basal bodies
Gene Protein Inheritance Disease Species Situs inversus Extraciliary locations References
PKD1 Polycystin-1 Autosomal-
dominant
ADPKD Human No Yes (lateral cell junctions;
focal adhesions;
cytoplasmic vesicles)
[47, 76]; Table 2
PKD2 Polycystin-2 Autosomal-
dominant
ADPKD Human Yes Yes (Endoplasmic
reticulum; lateral or
basolateral membrane;
lamellopodia)
[47, 83]; Table 2
PKHD1 Fibrocystin A ARPKD Human No Yes (cytoplasmic;
microvilli; apical actin
web)
[116–118]
OFD1 OFD1 X-linked OFDS Human No No [119]
NPHP1 Nephrocystin AR NPHP (juvenile) Human No Yes (focal adhesions) [120, 121]
NPHP2 Inversin AR NPHP (infantile);
inversin mouse
HumanMouse Yes Yes (nucleus, lateral cell
junctions)
[122–125]
NPHP3a NPHP3 AR NPHP (adolescent);
pcy mouse
HumanMouse No ? [126]
NPHP4a Nephroretinin;
nephrocystin-4
AR NPHP (juvenile) Human No ? [127, 128]
BBS4 BBS4 AR BBS Human Yes No [129]
BBS8 BBS8 AR BBS Human Yes No [130]
Cys1 Cystin AR Cpk mouse Mouse No No [131]
Tg737 Polaris AR Orpk mouse Mouse Yes No [47]
Abbreviations are: ADPKD, autosomal-dominant polycystic kidney disease; AR, autosomal recessive; OFDS, orofacial digital syndrome; NPHP, nephronophthisis;
BBS, Bardet-Biedl syndrome.
aInteraction with nephrocystin but ciliary localization has not yet been demonstrated.
and transduces the flow-activated asymmetric Ca2+ signal
detected at the left border of the node [58]. No lateral-
ity defects have been described in Pkd1−/− embryos. In
contrast, skeletal defects have been reported in several
Pkd1 null animals but not in Pkd2 knockouts.
In heterozygotes, renal and liver cysts are seen in older
animals but the phenotype is generally mild and highly
variable between animals [10, 56], with somewhat more
severe disease in transheterozygotes. [22] The mildness of
the disorder in heterozygotes contrasts with the human
condition but may simply reflect the difference in lifespan
between humans and mice since ADPKD is generally a
late-onset disorder. The development of liver cysts oc-
curs only in heterozygotes (not homozygotes) indicating
a central role for the polycystins in maintaining the biliary
architecture in the adult rather than during development
[27, 59]. Only the Pkd2WS25/− compound heterozygous
model, with a somatically unstable WS25 allele, devel-
ops adult-onset renal cystic disease in a rapid and repro-
ducible way and is presently the only orthologous model
of ADPKD in which to test potential therapies [11]. How-
ever, conditional knockouts of Pkd1 represent models of
PKD1 that may also be suitable for future therapeutic
testing.
Signaling pathways
Functional analysis of cells overexpressing heterol-
ogous PKD1 and PKD2, analysis of homology, and
identification of interacting partners (Table 4) have im-
plicated the polycystins in a number of key signaling
pathways. Polycystin-1 contains a G protein activation se-
quence (Fig. 1) which binds and activates several classes
of Ga subunits providing good evidence that it can func-
tion as a G protein coupled receptor. In addition, the
C-terminus of polycystin-1 has been shown to promote
activator protein-1 (AP-1) transcription via the activation
of several classes of G proteins including heterotrimeric
G proteins, Rac1 and cdc42 [60, 61]. Unexpectedly, coex-
pression of polycystin-2 has demonstrated both coopera-
tive and inhibitory effects on polycystin-1 downstream
signaling. For instance, ectopic polycystin-2 augments
protein kinase C–mediated AP-1 signaling by polycystin-
1 yet blocks polycystin-1–triggered G protein coupled
signaling in other cells [62, 63]. These results could im-
ply that the interaction between the polycystins results
in the differential activation of distinct pathways for spe-
cific effector functions in different cells. The C-terminus
of polycystin-1 can bind and stabilize RGS7, a regulator
of G protein signaling (RGS) molecule which is normally
rapidly degraded. [64] The stabilization of RGS7 could in
turn modulate a number of G protein–dependent signal-
ing cascades especially those activated by polycystin-1.
Exogenous overexpression of full-length PKD1 in
Madin-Darby canine kidney (MDCK) cells results in a
reduced proliferation rate, increased resistance to apop-
tosis, and the development of branching tubules rather
than cysts [65]. This possible role for polycystin-1 may be
linked to activation of the Janus kinase (JAK2) and sig-
nal transducers and activators of transcription (STAT)1/3
pathway with experimental evidence of the up-regulation
of p21waf1 leading to cell cycle arrest in G0/G1 [66].
Polycystin-2 was not required for JAK2 binding but was
necessary for JAK2 activation (by phosphorylation) [66].
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Cell-cell/matrix interactions
Homotypic polycystin-1 interactions (via the PKD do-
mains) that could mediate cell-cell contacts have been
described [67]. Cell-cell adhesion appears to be disrupted
by antibodies to this region that is partially overcome in
cells overexpressing polycystin-1 [68]. Heterophilic inter-
actions of polycystin-1 with the E-cadherin/catenin com-
plex have also been reported: these could contribute to
the maintenance of normal intercellular adhesion [42, 69].
Cystic ADPKD cells are defective in basolateral mem-
brane trafficking for lipids and certain proteins such as
E-cadherin and the low density lipoprotein-receptor
(LDL-R) that are retained in the Golgi [70]. It has
been postulated that mutant polycystin-1 may bind to
E-cadherin leading to its intracellular retention and re-
placement by N-cadherin [68, 69].
Polycystin-1 has also been localized to focal adhesions
and may form part of a focal adhesion complex medi-
ating cell-matrix adhesion, branching tubulogenesis and
cell migration [45, 65, 71, 72]. Cystic PKD cells display in-
creased adhesiveness to collagen I mediated by integrins
(a2b 1) suggesting that polycystin-1 and/or polycystin-2
may influence integrin-mediated signaling [45]. In addi-
tion, phosphorylation could act as the molecular switch
determining whether polycystin-1 is enriched in cell-cell
or cell-matrix complexes [73].
Channel activity
The close resemblance of polycystin-2 (and polycystin-
2-like proteins) to TRP-gated channels has led to a num-
ber of studies attempting to demonstrate that polycystin-2
can reconstitute a Ca2+ channel. There is now good
evidence that polycystin-2 conducts divalent cations, in-
cluding Ca2+, although the major cellular site of channel
activity remains controversial [53, 74–76]. A further ques-
tion is how much polycystin-2 channel function depends
on the presence or activity of polycystin-1. In artificial
lipid bilayers, recombinant polycystin-2 can reconstitute
Ca2+ channel activity in the absence of polycystin-1;
polycystin-1 appears to stabilize or activate polycystin-
2 channel activity in this system [77]. In another study,
however, whole cell currents were only induced by
coexpression of polycystin-1 and polycystin-2; mutants
unable to interact did not induce channel activity suggest-
ing that this interaction was crucial. [53] In this system
(CHO cells), polycystin-1 was required to transport
polycystin-2 to the plasma membrane. In contrast, a third
study found that polycystin-2 had the characteristics of a
calcium-activated, high-conductance endoplasmic retic-
ulum channel with a role in the release of intracellular
Ca2+ from the endoplasmic reticulum [75]. One com-
mon theme from all these studies is that polycystin-2
plays a role in increasing cytoplasmic levels of Ca2+.
Consistent with this function, cells haploinsufficient for
Pkd2 have a lower resting level of intracellular Ca2+ and
store-operated Ca2+ (SOC) channel activity is also down-
regulated [26]. The ability of polycystin-1 to reconstitute
channel activity by itself or form part of a channel pore,
possibly with other subunits, has not yet been shown. In
some systems, heterologous expression of full-length or
C-terminus of polycystin-1 alone can activate a nonselec-
tive calcium current [78] which could be independent of
polycystin-2 [79].
IS THERE A COMMON CILIARY CYSTIC
PATHWAY?
Most vertebrate cells express a single nonmotile cilium
(primary cilium) with a characteristic “9 + 0” microtubule
structure arising from a basal body or centriole (see
Fig. 2). In the kidney, all tubular epithelial cell types (ex-
cept intercalated cells) express a cilia projecting into the
lumen of the tubule. Although this organelle had been
recognized for over 100 years, until recently its precise
function was obscure [80]. Data from a number of differ-
ent sources now suggest that the primary defect in various
forms of PKD, including ADPKD, may relate to abnor-
malities of ciliary structure or function. Compelling evi-
dence has come from animal models, protein localization
studies (see Table 6 for details), disruption of ciliary pro-
teins, and direct functional evidence in model systems.
The first clue directly linking PKD and primary cilia
came from the orpk mouse model of PKD when it was dis-
covered that the defective protein, polaris, is orthologous
to the Chlamydomonas intraflagellar transport (IFT) pro-
tein IFT88 [81]. Mice null for the gene Tg737 or with
a hypomorphic allele, Tg737orpk, have left-right axis de-
fects and absent or stunted primary cilia [81]. Other early
evidence linking primary cilia to PKD came from the
study of C. elegans orthologues of the ADPKD genes,
lov-1 and PKD2 [31]. Mutants of these genes have spe-
cific male mating behavior defects related to a failure of
mechanosensation mediated by a specific set of ciliated
sensory neurons. These are also the major sites of ex-
pression of the C. elegans polycystins [31]. Functional ev-
idence directly linking the induction of structural ciliary
abnormalities to the subsequent development of PKD
has come from the demonstration that a kidney-specific
conditional knockout disrupting a ciliary motor subunit
gene, Kif3a, in tubular epithelial cells results in a cys-
tic phenotype [82]. Simultaneously, a number of proteins
associated with PKD in both mice and/or humans have
been localized to primary cilia or to the basal body in-
cluding polycystin-1 and polycystin-2 (see Table 6) [47,
83]. Recently, an insertional mutagenesis screen for cys-
tic mutants in Zebra fish larvae has revealed selective
enrichment for the orthologues for several IFT proteins
and pkd2. This finding adds further weight to the primary
importance of ciliary abnormalities in PKD pathogenesis
[84].
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Fig. 2. Two models of polycystin-
1/polycystin-2 function. The polycystin-
1/polycystin-2 complex could function as a
mechanosensory calcium channel localized
in primary cilia (A) and/or as an adhesion
complex with or without E-cadherin (B).
A solitary primary cilium arising from a
human proximal tubular cell (DAPI nuclear
stain) can be visualized using an antibody
to acetylated tubulin (red) (panel A).
Polycystin-1 expression (green) colocalizes
with acetylated tubulin expression (panel B).
In (panel A), polycystin-1 expression in a
PKD1 transgenic collecting duct cell, M7, is
greatly increased compared to that of a con-
trol cell, M8. Polycystin-1 is shown outlining
the lateral cell borders of a cell monolayer
indicating a potential role in mediating
cell-cell adhesion. Cis- and trans-homophilic
interactions between the Ig-polycystic kidney
disease (PKD) domains of polycystin-1 could
mediate cell-cell adhesion and/or signaling.
The polycystin complex could be anchored to
the cytoskeleton through a number of actin-
binding adapter proteins (orange diamond)
which link the C-terminus of polycystin-2
to actin filaments and via the direct binding
of the C-terminus of polycystin-1 to inter-
mediate filament proteins such as vimentin
and cytokeratin (see Table 4). Abbreviations
are: p1, polycystin-1; p2, polycystin-2; RyR,
ryanodine receptor; CM, ciliary membrane;
LM, lateral (plasma) membrane; E-cad,
E-cadherin. For other possible locations and
functions of the two proteins, please refer to
Tables 2 to 4.
A mechanosensory function for renal primary cilia
had previously been suggested since flow-induced ciliary
bending leads to a rise in intracellular Ca2+ [85]. There
is now experimental data to indicate that a ciliary poly-
cystin complex acts as the mechanosensor and that the
polycystin-2 channel mediates the flow-sensitive influx of
extracellular Ca2+ [76]. These results suggest that a de-
fect in ciliary mechanosensation due to PKD1 or PKD2
mutations results in the disruption of Ca2+ influx and this
somehow leads to cyst development. Other possible roles
for primary cilia have been suggested (e.g., as a sensor of
tubular lumen diameter) acting as an important check-
point in tubule maturation with resultant cystic expansion
when defective [86].
One note of caution to an exclusive “ciliary model” of
PKD is indicated by a recent study showing that restora-
tion of ciliary length in the orpk model by transgenic ex-
pression of Tg737 corrected the left/right axis defects but
did not prevent cyst development [87]. It is unclear, how-
ever, if the restored kidney cilia are fully functional in this
experimental system; it also appears that the transgenic
cDNA used does not express all known splice forms of the
Tg737 gene. Nonetheless, an alternative explanation that
some splice forms of polaris have extraciliary functions
in epithelial cells (analogous to inversin) and that these
could be important in suppressing cystogenesis [80]. As
shown in Table 6, it should be noted that not all of the
PKD proteins are associated with situs inversus (indica-
tive of nodal ciliary dysfunction) and several have been
shown to have prominent extraciliary locations as well as
significant interactions with nonciliary proteins. Since the
timing and prominence of cystic disease can vary greatly
between these diseases (e.g., cysts are usually a late and
minor feature in nephronopthisis), the extraciliary func-
tions of these proteins could have biologic significance
both for cyst formation as well as in the pathogenesis of
other features in the diseased kidney (see later).
HOW IS POLYCYSTIN DYSFUNCTION LINKED
TO CYST DEVELOPMENT?
Structural and functional analysis of the polycystins has
provided clues as to several possible roles for these pro-
teins but do not as yet offer a unifying explanation as to
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how the complex might act. Figure 2 shows two possi-
ble models through which the polycystin complex could
act—as a flow-activated mechanosensitive channel lo-
cated in primary cilia or alternatively as a ligand-activated
and/or mechanosensory adhesion complex involved in
mediating cell adhesion. The ciliary function of the poly-
cystin complex has been discussed above but there is also
strong evidence that the polycystin complex might medi-
ate cell adhesion. In this regard, it has been shown that
the C-terminus of polycystin-2 can bind to several adap-
tor proteins which bind actin whereas the C-terminus of
polycystin-1 has the ability to bind directly to interme-
diate filaments (Table 4). Both these attachments would
anchor the complex firmly to the cytoskeleton and per-
haps modulate its function. These two models need not be
mutually exclusive since it is possible that more than one
defect in polycystin function could be required for cyst
development. Potential abnormalities in ciliary function
could initiate cyst formation while defects at extraciliary
locations could contribute to cyst expansion or some of
the other features associated with progression of a cys-
tic phenotype. Experimental models in which the ciliary
and extraciliary functions of the polycystin complex can
be clearly distinguished would yield further insights into
this important question.
The best characterized function of the polycystins is as
a Ca2+ channel and it seems likely that a disruption of
normal intracellular Ca2+ homeostasis may be the cen-
tral defect underlying the ADPKD phenotype. Neverthe-
less, several different models of PKD have also suggested
a central role for another second messenger molecule,
cyclic adenosine monophosphate (cAMP), in cyst devel-
opment. Agonists of cAMP stimulate fluid secretion in
collecting ducts and ADPKD cysts [88]. In addition, cells
isolated from PKD kidneys have an altered proliferative
response to adenylate cyclase agonists with activation of
the extracellular-regulated kinase (ERK) signaling cas-
cade compared to an inhibitory effect in normal kidney
cells [89]. This phenotypic switch could contribute to the
excess proliferation seen associated with PKD. There is
also evidence of cross-talk between Ca2+ and cAMP sig-
naling pathways in PKD so changes in intracellular Ca2+
concentrations could also stimulate an altered response
to cAMP [90].
TREATMENT PROSPECTS FOR ADPKD
Recently, several promising treatments arising from a
greater understanding of the pathophysiology of PKD
have been tested in animal models of PKD, including
some orthologous to human disease. The compounds
tested were designed to target the down-stream effects
of cystic transformation, rather than the primary genetic
defect itself. Figure 3 shows that cystic transformation
may have multiple downstream consequences leading to
the typical appearances of the end-stage ADPKD kidney.
Pharmacologic strategies targeting these pathways might
therefore be useful to preventing or delaying progression
to end-stage kidney failure.
Many of the animal models used so far have not been
orthologous to ADPKD but an effective treatment in
one model may prove to be useful in ADPKD given
the common phenotypic changes found in most forms
of PKD. Epidermal growth factor (EGF) and a related
molecule, transforming growth factor-a (TGF-a), have
been shown to promote epithelial cell proliferation and
cyst development in PKD. Cyst fluids contain mitogenic
quantities of these growth factors; moreover the EGF
receptor (EGFR) and EGFR-related tyrosine kinase re-
ceptor (Erb-B2) are overexpressed and mislocalized to
the apical membrane in ADPKD and other rodent mod-
els of PKD. Compounds that inhibit EGFR tyrosine
kinase activity markedly inhibit cyst development and
progression in three of these models [91]. However, it
remains to be seen how effective these compounds will
be in models orthologous to ADPKD since a deleteri-
ous effect was recently reported with treatment in the
Pck model of ARPKD [92]. Another possible treatment,
pioglitazone (a thiazolidinedione), prolonged survival of
Pkd1−/− embryos and reduced cardiac defects and re-
nal cystogenesis when administered maternally [55]. This
compound could correct some of the downstream effects
of polycystin dysfunction, such as the reduced levels and
mislocation of b-catenin. Improved endothelial function
was also noted following prolonged treatment of Pkd1+/−
mice but its effect on cyst development in the heterozy-
gote has not yet been reported.
Promising results using a new drug (OPC31260), de-
signed to reduce intracellular concentrations of cAMP in
PKD by targeting the vasopressin V2 receptor (VPV2R),
the major cAMP agonist in the collecting duct, have also
been reported. Treatment dramatically inhibited disease
development, halted and even caused regression of es-
tablished disease in the PCK rat (model of ARPKD)
and pcy mouse (model of nephronophthisis NPHP3)
[93]. Furthermore, treatment of the Pkd2WS25/− model
of ADPKD with OPC31260 also markedly inhibited re-
nal enlargement and cyst progression in this model [94].
OPC31260 appears to be a safe treatment with remark-
ably few side-effects, possibly due to the restricted expres-
sion of VPV2R to the principal cells of the collecting duct.
It seems likely that one or more of these compounds will
be tested in human ADPKD in the near future, opening
a new chapter in the history of this disorder.
CONCLUSION
The molecular analysis of ADPKD has begun to clar-
ify the complex phenotype of this condition. However, it
has also revealed the complexity of the genes and proteins
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Fig. 3. Pathophysiology of disease progres-
sion in the cystic autosomal-dominant poly-
cystic kidney disease (ADPKD) kidney. Com-
pared to the normal kidney (A), the end-
stage ADPKD kidney (B) is characterized by
glomerular sclerosis, interstitial fibrosis, and
tubular atrophy associated with a prominent
inflammatory cell infiltrate (arrowheads). As
shown in (B), apart from tubular cysts (c),
the glomeruli (g) may be cystic or sclerosed
(magnification ×100). A schematic model for
disease progression in ADPKD kidney shows
that it is likely that somatic mutations in
PKD1, PKD2, or other genes (e.g., TSC2)
and/or stochastic factors trigger the entry of a
predisposed cell bearing a germ line PKD1 or
PKD2 mutation into a cystic pathway result-
ing in a number of downstream deleterious
effects on fluid transport, cell turnover, and
interstitial scarring. The initiation and impact
of these processes could in turn be modulated
by nonallelic (“modifying genes”) or environ-
mental factors acting at each stage (indicated
by ?).
that are involved, their likely multiple roles and the many
possible downstream consequences of mutation. Never-
theless, we now have a greater understanding of ADPKD
pathophysiology and a number of new treatment options.
The rapid pace of the advances being made hold great
promise for patients with this previously untreatable dis-
ease. To summarize, (1) polycystin-1 and polycystin-2 are
cardinal members of a new protein family (the eight mem-
bers that have been identified so far can be subdivided
into “PKD1-like” and “PKD2-like” proteins); (2) a vari-
ety of functions have been attributed to polycystin-1 but
there is general consensus that polycystin-2 functions as a
cation channel; (3) significant phenotypic differences be-
tween Pkd1 and Pkd2 knockout mice indicates that these
proteins have overlapping as well as independent func-
tions; (4) a number of key signaling pathways regulated
by the polycystins, especially controlling cell proliferation
and fluid secretion, have been described; (5) there may
be several mutational mechanisms underlying cyst for-
mation in ADPKD; (6) abnormalities of ciliary structure
and function may underlie the PKD phenotype; and (7)
several new therapies showing promise in rodent PKD
models merit testing in humans.
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